HC Wainwright Analysts Decrease Earnings Estimates for KYTX

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - HC Wainwright lowered their FY2024 earnings per share estimates for Kyverna Therapeutics in a research report issued on Wednesday, November 20th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($3.14) per share for the year, down from their previous estimate of ($3.01). HC Wainwright has a "Neutral" rating and a $6.00 price objective on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.31) per share. HC Wainwright also issued estimates for Kyverna Therapeutics' Q4 2025 earnings at ($0.77) EPS.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.01. The company had revenue of $0.01 million for the quarter.

A number of other equities analysts have also commented on the company. UBS Group began coverage on Kyverna Therapeutics in a research note on Thursday, October 10th. They set a "buy" rating and a $13.00 price target for the company. Rodman & Renshaw started coverage on Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a "buy" rating and a $16.00 target price on the stock. Wells Fargo & Company reduced their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, November 15th. RODMAN&RENSHAW raised Kyverna Therapeutics to a "strong-buy" rating in a report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. decreased their price objective on Kyverna Therapeutics from $39.00 to $33.00 and set an "overweight" rating for the company in a report on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $25.71.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ KYTX traded up $0.30 during mid-day trading on Friday, reaching $4.29. The company's stock had a trading volume of 228,034 shares, compared to its average volume of 454,495. The stock has a fifty day moving average of $5.22 and a two-hundred day moving average of $8.21. Kyverna Therapeutics has a 52 week low of $3.92 and a 52 week high of $35.06.

Institutional Trading of Kyverna Therapeutics

Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD acquired a new stake in shares of Kyverna Therapeutics in the first quarter valued at $23,093,000. Novo Holdings A S increased its holdings in Kyverna Therapeutics by 150.0% in the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company's stock valued at $13,125,000 after buying an additional 1,050,000 shares during the last quarter. E Fund Management Co. Ltd. purchased a new position in Kyverna Therapeutics in the second quarter valued at $1,421,000. Great Point Partners LLC increased its holdings in Kyverna Therapeutics by 232.8% in the second quarter. Great Point Partners LLC now owns 499,152 shares of the company's stock valued at $3,744,000 after buying an additional 349,152 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new position in shares of Kyverna Therapeutics during the first quarter worth about $15,041,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.